[The therapy of acute myelogenous leukemia].
In the last few years tremendous progress has been made in the treatment of acute myelogenous leukemia: remissions have been observed more frequently and they last longer. Present-day therapy is described. It has become so complex that induction therapy must be carried out by oncologic departments. Maintenance treatment can however be conducted by the family physician, acting in close cooperation with the oncology unit.
D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008130:Lomustine / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use
D003561:Cytarabine; D008130:Lomustine; D003520:Cyclophosphamide; D013866:Thioguanine; D003630:Daunorubicin
Die Therapie der akuten myeloischen Leukämie